Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands
Bart Hoogveldt1, Benoît Rive2, Johan Severens3, Khaled Maman4, Chantal Guilhaume51Field Product Management, Lundbeck BV, Amsterdam, The Netherlands; 2Global Outcomes Research, Lundbeck SAS, Issy-les-Moulineaux, France; 3Institute of Health Policy and Management, Erasmus University Rott...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2011
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/a6fa6c52e8cd4672a1cdb96a20e5ca86 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Bart Hoogveldt1, Benoît Rive2, Johan Severens3, Khaled Maman4, Chantal Guilhaume51Field Product Management, Lundbeck BV, Amsterdam, The Netherlands; 2Global Outcomes Research, Lundbeck SAS, Issy-les-Moulineaux, France; 3Institute of Health Policy and Management, Erasmus University Rotterdam, The Netherlands; 4Creativ Research SAS, Paris, France; 5Global Evidence and Value Development, Sanofi-Aventis, Paris, FranceObjective: The purpose of this study was to estimate the cost-effectiveness of memantine relative to standard care in patients with moderate-to-severe Alzheimer's disease in the Netherlands.Methods: A country-adapted five-year Markov model simulated disease progression through a series of states, defined by dependency and disease severity. Transition probabilities were derived from trials, with utility and epidemiological data obtained from a longitudinal Dutch cohort. Cost-effectiveness was described in terms of quality-adjusted life years and time spent in a nondependent state or in a moderate severity state.Results: Memantine monotherapy versus standard care led to 0.058 quality-adjusted life years gained (1.207 versus 1.265), longer time in a nondependent state (from 1.602 to 1.751 years) and in a moderate state (from 2.051 to 2.141 years), and no additional costs (€113,927 versus €110,097). Robustness of results was confirmed through sensitivity analyses.Conclusion: Memantine is dominant compared with standard care in the Netherlands. Results are consistent with similar economic evaluations in other countries.Keywords: memantine, Alzheimer's disease, cost-effectiveness analysis, Netherlands, cholinesterase inhibitors |
|---|